{
  "id": 20609219,
  "title": "FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK",
  "url": "https://urgent.news/2026/11/18/fda-publishes-rejection-letter-for-summit-drug-nuvalent-buyout-pays",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-18T14:21:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/summit-crl-sellas-data-nelkarmi-lilly-astrazeneca-biogen/874825/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 4,
    "also_reported_by": [
      {
        "outlet": "Seeking Alpha News",
        "title": "GSK wins FDA nod for lung cancer therapy added from Nuvalent buyout",
        "url": "https://urgent.news/2026/11/17/gsk-wins-fda-nod-for-lung-cancer-therapy-added-from-nuvalent-buyout",
        "published": "2026-11-17T18:26:44.000Z"
      },
      {
        "outlet": "Investing.com",
        "title": "GSK wins FDA approval for lung cancer drug Nelkarmi",
        "url": "https://urgent.news/2026/11/17/gsk-wins-fda-approval-for-lung-cancer-drug-nelkarmi",
        "published": "2026-11-17T18:48:19.000Z"
      },
      {
        "outlet": "Quartz",
        "title": "GSK won U.S. approval for its second lung cancer drug from the Nuvalent deal",
        "url": "https://urgent.news/2026/11/17/gsk-won-u-s-approval-for-its-second-lung-cancer-drug-from-the",
        "published": "2026-11-17T19:00:23.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}